Investor Relations

Hemab Therapeutics is a clinical-stage biotechnology company developing therapeutics that reimagine the treatment of blood coagulation disorders to sustain life and human resilience. Based in Cambridge, Massachusetts and Copenhagen, Denmark, Hemab Therapeutics’ mission is to build the leading coagulation company by discovering, developing, and commercializing innovative therapies for the millions of patients worldwide suffering from serious bleeding and thrombotic diseases. Coagulation disorders, such as Glanzmann thrombasthenia, Factor VII Deficiency and Von Willebrand Disease, encompass a broad and heterogeneous group of conditions, and many patients experience significant life-long disease burden due to either a lack of available prophylactic therapies or limitations associated with existing treatment approaches.